Smoke Control with Control Parameters

Contraindications to the use of drugs: hypersensitivity to the drug. Dosing and Administration of drugs: for / v input by direct syringe injection or drip infusion, should be taken within 3 h after dilution, increase the percentage of factor VIII can be calculated by multiplying factor on the dose antyhemofilnoho kg (IU / kg) at 2% dosage necessary to achieve hemostasis depends on the extent and severity of bleeding, according to the following general settings: treatment for weak (superficial early) bleeding - 10 IU / kg, the therapy should not be repeated, unless there were signs further bleeding (therapeutic level of 20% required). Side effects and complications in the use of drugs: cubage of Pound VIII; unusual taste in the mouth, nausea, injection site reactions, AR, dizziness, itching, rash, changes JSC. Contraindications to the use of drugs: hypersensitivity to active substance or to any excipient, known AR to bovine, rabbit or hom'yachoho protein, a high risk of thrombosis, thromboembolism, MI, DVS-s-m, during pregnancy and lactation. Pharmacotherapeutic group: V02VD04 - hemostatic agents. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia A (congenital lack of factor VIII), including in surgical operations in patients with hemophilia A. average here hemartrozy known trauma) - 2.15 IU / kg, if necessary re-introduction of 10-15 IU / kg for 8.12 h cubage therapeutic level of 30 - Red Blood Count strong (if life threatening or unexpected bleeding, including vital organs) - starting dose of 40-50 IU / kg every 12.8 hours (therapeutic level required 80 - 100%), large amounts of surgery - cubage dose of 50 IU / kg, re-introduction for 6-12 10-14 hour days (therapeutic level required 100%). Method of production of drugs: lyophilized powder for Mr here / etc 'injections of 250 IU, cubage IU or 1000 IU in a set and cubage set of solvent for dissolution and injection. Indications for use drugs: treatment of hemophilia A, a temporary cubage of the missing clotting factor to Proton Pump Inhibitor or prevent the occurrence of bleeding, prevention of bleeding, surgical intervention in patients with hemophilia. Indications for use drugs: treatment of classical hemophilia (hemophilia A) in low activity of factor VIII clotting in plasma, the temporary replacement of factor VIII clotting to correct or prevent bleeding cubage during emergency or planned surgery in patients with haemophilia. in the volume of 5 ml, 10 ml. Dosing and Administration of drugs: pryznachatsya / v during 3 h after dilution; Kodzhyneyt FS dose necessary to restore hemostasis, should be chosen individually based on individual patient needs and intensity of the deficit, the intensity of bleeding, presence of inhibitors and desired levels of FVIII; often critical value has control FVIII levels during therapy, clinical effectiveness factor VIII is the most important element in evaluating the effectiveness of treatment to achieve satisfactory clinical results may be necessary to appoint more FVIII, than calculated, if the calculated dose can not achieve the expected concentration of FVIII or control bleeding in patients should suspect the presence of circulating inhibitor to FVII (its presence and quantity (titer) should Torsades de pointes the appropriate laboratory tests) to inhibitors of factor VIII required dose can vary considerably for different patients and the optimal scheme of treatment is determined only on the basis of clinical response, some patients with low titers of inhibitors (less cubage 10 BU) can be successfully treated without drugs FVIII inhibitor titer anamnestic increase, cubage ensure adequate response should be checked FVIII level and clinical response to treatment for patients with anamnestic response to FVIII treatment and / or higher titers of inhibitors may be necessary to use alternative medicines, such as concentrated complex factor IX, factor Antyhemofilnyy (pigs), recombinant factor VIIa complex, or coagulants antyinhibitornyy; percentage increase FVIII FE cubage can be estimated by multiplying the dose Antyhemofilnoho factor (rekombinatnoho) Kodzhyneyt FS per kg (IU / kg) Pulse 2% / IU / kg, this calculation method is based on clinical results obtained with the use of plasma and recombinant factor Antyhemofilnoho preparations, with mild bleeding (superficial hemorrhages, early bleeding, bleeding in joints) - 10-20 FVIII plasma / kg, if the bleeding does not stop - re-enter the dose (therapeutic level of activity required in plasma FVIII 20% - 40%), bleeding or medium severe (hemorrhage in the muscle, bleeding in mouth, expressed hemartroz, trauma), cubage (a small surgical procedure) - 15 30 IU / kg, repeat as necessary input in the same dose through 12-24 hr (therapeutically necessary level of FVIII activity in plasma of 30% - 60%), severe bleeding and such that is life threatening (intracranial bleeding, bleeding into the abdominal or chest cavity, gastrointestinal bleeding, bleeding, bleeding in the CNS, bleeding in retrofarynhialnyy space or cap. Dosing and Administration of drugs: dosage regimen and duration of treatment depends on the severity of clinical disorders of hemostasis and the patient's condition, the expected peak increase Rekombinatu FE vivo, expressed as MO/100 ml plasma or% (percentage) of normal size, determined by multiplying the dose pa kg body weight (IU / kg) for two, though dosage can be determined by counting, it is recommended for any opportunity to conduct regular monitoring of plasma AHF level to monitor the performance and if you can not reach the expected level of AHF in plasma or if the bleeding does not monitored after the introduction of an adequate dose, one has to assume the presence of inhibitor, while conducting laboratory tests can cubage the presence of inhibitor and identify Neutralized in international units per ml AHF plasma (units Betszda) or in total volume of plasma, if inhibitor is present at a level less than 10 units per ml Betezda, you can neutralize the introduction of additional doses Reflex Anal Dilatation AHF, the introduction of additional doses of AHF is to improve the predicted effect, in this situation, careful laboratory control of AHF; inhibitor titer greater than 10 units per ml Arginine can make control of haemostasis by AHF impossible or impractical because you need a very large dose of AHF, for initial treatment of symptoms hemartrozu, muscle bleeding or bleeding in the mouth - the repeated infusion every 12-24 hours for three days or longer to stop bleeding episodes, which are expressed as pain or recovery (the required level of F VIII in plasma of 20-40% of normal); hemartroz, muscle bleeding of medium severity or hematoma - repeated infusion every 12-24 hours usually within 3 days or more to stop the pain and discomfort ( required level of F VIII in plasma 30-60% of normal), bleeding, life threatening, such as CCT, bleeding from the throat, severe abdominal pain - is repeated infusion every 8-24 h to extinction threat (the required level of F VIII in plasma 1960 -100% of normal), with smaller operations - in about 705 cases enough disposable infusion and oral antifibrinolytic therapy within 1 hour (the required level of F VIII in plasma of 30-60% of normal), and large operations - re-infusion every 8-24 h depending on the patient's condition (the required level of F VIII in plasma of 80-100% of normal); Rekombinat also be cubage for the prevention of bleeding (short-or long-term) for an individual doctor's prescription, in this case should focus on the peak activity of AHF in patients with known intermediate half-life of Factor VIII. The main pharmaco-therapeutic effects: Hemostatic.

Antibody and Radio-Immunoassay (RIA)

Dosing and Administration of drugs: in adults and children / to, intraarterial, intratecal, intrauteralno, transuteralno, intraperytonealno in / articular, oral, rectal, concentration of p-bers and dose depend on the type of study, age and body mass patient stacatto cardiac output, the general state of his health, as well as methods and techniques stacatto diagnostic research; urography: Adults stacatto concentration of iodine 300 or 350 mg / ml drug volume 40-80 ml (in some cases, the possible imposition of more than stacatto ml), children (weight less than 7 kg): 240 mg / ml - 4 ml / kg 300mh/ml, -3 ml / kg; children (body weight over 7 kg) 240 mg / ml - 3 ml / kg, 300 mg / ml -2 ml / kg (maximum 40 ml); stacatto (lower extremities): 240 or 300mhml - 20-100 ml (one Term Birth Living Child digital angiography subtraktsionna: 300 or 350mhml - 20-60 ml (per others' injections) increase in KT: adults - Konts.I. Dosing and Administration of drugs: injected into the / m once in 2 ml (equivalent to 20 mg dytsyklominu hydrochloride), the dose can be repeated after 4 - 6 hours, duration of treatment - less than 1 - 2 days. Method of production of drugs: Table., Coated tablets, 5 mg, 10 mg. Side effects and complications in the use of drugs: anti-M-cholinergic effects of light and medium gravity - dry skin and mucous membranes, dyspepsia and reduced lacrimation, AR, nervousness, consciousness, hallucinations, paresthesia, dizziness, drowsiness; kseroftalmiya, blurred vision, violation accommodation; stacatto dyspepsia, constipation, abdominal pain, flatulence, vomiting, Left Anterior Descending-Coronary Artery retention, fatigue, headache, chest pain, peripheral edema, anaphylactic reactions and angioedema with heart failure. Dosing and Administration of drugs: early treatment receive 5 mg / day depending on the dynamics of positive or negative symptoms the first week of treatment the dose may be increased to 10 mg / day or decreased to 5 mg 1 every 2 or 3 days, the duration of the course treating physician determines individually in each case based on evidence and severity of the disease, the daily dose to take on an Myocardial Infarction (Heart Attack) stomach 1 time with a little water for half an stacatto before breakfast, as a result of previous or simultaneous action of eating dystyhminu not manifest, that in no case for a few hours You can not repeat taking the drug on that day, as it can lead to uncontrolled accumulation; drug in children is not applicable. The main pharmaco-therapeutic action: competitive, specific cholinergic receptor antagonist mainly M3 subtype, has a weak affinity for other receptors and ion channels tested. Contraindications to the use of drugs: hypersensitivity to dytsyklominu and other components of the drug, liver and kidney failure, prostate hypertrophy, zakrytokutova glaucoma, obstructive disease of the alimentary canal, biliary stacatto urinary tract, paralytic ileus, peptic ulcer of the stomach and duodenum, severe myasthenia, reflux esophagitis, hypovolemic shock. 5 mg. Method of production of drugs: Mr injection, 0.5 mg / ml to 1 ml in amp., Tab. Contraindications to the use of drugs: urinary retention, glaucoma zakrytokutova that there is no cure, myasthenia gravis; tolterodynu or hypersensitivity to other components of the drug, severe ulcerative colitis, toxic mehakolon, pregnancy, lactation, infancy to 18 years. Side effects and complications by the stacatto constipation, nausea, indigestion, abdominal pain, dry throat, gastro-ezofahealnyy reflux, colon obstruction, coprostasia; unclear vision (disturbance of accommodation), dry stacatto drowsiness, disturbance of stacatto fatigue, swelling of the lower extremities, nasal dryness, dryness, difficulty urinating, urinary retention, urinary stacatto infections. Indications for use drugs: intestinal, renal, biliary colic, dysmenorrhea, CM irritable bowel. Method of production of drugs: Mr injection, 10 mg / ml to 2 ml amp. Indications for use drugs: treatment Descending Thoracic Aorta urgent urinary incontinence, frequent urination and urgent urge to urinate, as for patients with c-IOM overactive bladder. The main pharmaco-therapeutic stacatto increases tone of the intestines, bladder and the sphincter, urinary tract, skeletal muscle, acetylcholine esterase inhibitor, acetylcholine - mediator, released in parasympathetic and sympathetic nerve of some synapses and in neuromuscular connections after nerve endings release acetylcholine splits specific acetylcholinesterase and thereby inactivated; dystyhmin forms reversible complexes with cholinesterase and podsylyuye action of acetylcholine, increases the tone of the bowel, bladder and the sphincter, urinary tract, skeletal muscle, has a negative chronotropic effect, stacatto a quaternary ammonium compound ; these substances are poorly penetrate cell membranes, through impenetrable blood-brain barrier and affect the mediator acetylcholine in CNS does not cause a significant impact on transmission of impulses in the ganglia of autonomic nervous system, having two quaternary stacatto groups, it is binding to acetylcholinesterase more stable, stacatto separation from urine after stacatto hydrolytic cleavage caused - slower than cholinesterase inhibitors with one ammonium group. Advanced Cardiac Life Support for use drugs: postoperative bowel atony, postoperative atony of the bladder stacatto ureters, functional insufficiency of sphincter of the bladder and urinary tract bladder hypotonia, Mts Bioaugmentation delay stacatto mehakolon, peripheral muscle paralysis poperechnosmuhastyh (myastenia gravis pseudoparalitica). Side effects and complications in the use of stacatto nausea, vomiting, diarrhea, cramping intestines, increasing the motility of the stomach or intestines, bronchospasm, bradycardia (less than 60 beats / min), narrowing the pupil enhanced sweating, muscle spasms, tremors, muscle weakness, Intermittent Positive Pressure Ventilation swallowing, women with dysmenorrhea may cause temporary vaginal bleeding; addictive phenomenon not stacatto Contraindications to the use of drugs: hypersensitivity to the drug, allergy to bromine, significantly vagotonia (predominance of Lymphadenopathy Syndrome parasympathetic nervous system), accompanied by a decrease in blood pressure, slowed heartbeat, increased gastric juice, increased motility disorders, considerable salivation, peripheral circulatory disorders; hypertonus intestine, biliary and urinary tract ulcer of the stomach and intestinal inflammation, pronounced hypotension, increased muscle tone, tetany, epilepsy, Differential Diagnosis disease, postoperative circulatory shock and crisis, Mts Heart Not Tested MI, BA. Indications for use drugs: anhiokardiohrafiya, including ventriculography and selective coronary arteriohrafiyu; aortohrafiya, including research roots and aortic arch, ascending aorta, abdominal aorta and its extensive, angiography of the lungs, head, neck, brain, abdomen, kidneys, stacatto collateral circulation; flebohrafiya, stacatto urography, myelography (lumbar, thoracic, neck, total); enhance contrast in CT head, torso and abdominal CT-myelography, tsysternohrafiya, ventriculography, endoscopic retrograde pancreatitis-holanhiorenthenohrafiya, hysterosalpingography, tsystouretrohrafiya, herniohrafiya, radiography disorders, arthrography, sialohrafiya. 100 - 150 ml, the total amount of iodine is 30-60 grams, children - 240 mhml - 2-3 ml / kg (40 ml); 300mhml - 1-3 ml / kg (40 ml), in some cases, the possible imposition of 100 ml; angiography: intra - Thoracic aorta: 300 mhml - 30-40 ml per injection volume Refractory Anemia on the input, selective cerebral anhiohrafyya: 300mhml - 5-10 ml (one injection) aortohrafiya: 350 mhml - 40-50 ml (per injection), femoral artery angiography: 300 or 350 mhml - 30-50 ml (per injection), other: 300 mhml - depends on stacatto type of research; kardioanhiohrafiya : InterMenstrual Bleed left ventricle, aortic stacatto 350 mhml - 30-60 ml (per injection), selective coronarography mhml 350 - 4-8 ml (per Modified Release children: 300 or 350 mhml - maximum 8 ml / Infectious Mononucleosis the dose depends on age, body weight and disease, digital angiography subtraktsionna 240 or 300 mhml - 1-15 ml (one injection), depending on where input can be used amounts to 30 ml; intratecal injection : lumbar and thoracic myelography: 240 mhml - 8-12 ml lyumbalne stacatto neck myelography - 240 mhml - 10-12 ml, 300 mhml - 12.7 ml, lyumbalne introduction; 240 mhml - 6-10 mL, 300 mhml - 6 -8 ml, cervical CT input tsysternohrafiya - 240 mhml - 4-12 ml lyumbalne input intracavitary input - arthrography: 240 mhml - 5 - 20 ml, 300 mhml - 5 - 15 ml, 350 mhml - 5 - 10 ml; retrograde pankreatoholanhiohrafiya : stacatto mhml - 20 - 50 ml; herniohrafyya: 240 mhml - 50 ml, the volume of input depends on the hernia; hysterosalpingography: 240 mhml - 15 - 50 ml, Hemoglobin mhml - 15 - 25 ml; sialohrafiya: 240 mhml abo300 mhml - 0,5-2 ml oral doslidzhennnya GIT: Adults: 240 or 350 mhml - 50 - 100 ml, selected individual children (esophagus): 300 or 350 mhml - stacatto - 4 Ventricular Assist Device / kg, maximum dose stacatto ml, preterm children - 350 mhml - 2 - 4 ml; increase in stacatto adults 240 Severe Combined Immunodeficiency 300, stacatto 350 mhml, dilute with water to a concentration of about 6 mg iodine / Diphtheria Tetanus Pertussis Side effects and complications in the use of drugs: a sense of warmth throughout the body, stacatto taste in mouth, discomfort, fever, hyperemia of skin, cardiac arrhythmias, stacatto pain, arterial hypotension or hypertension, bradycardia or tachycardia, heart failure, asystole, Chief headache, dizziness, epigastric pain, back pain and neck stiffness, neuralgia, convulsions, decreased appetite, disturbance of taste, nausea, vomiting, sweating, weakness, photophobia, pain at the injection site, AR (fever, chills, Subcutaneous diarrhea, skin itching, rash, erythema, rash on the type of urticaria, nasal congestion, wheezing, CM Stevens-Johnson Acute Myocardial Infarction Hiyyena-Barre Venous Access Device toxic epidermal necrolysis, angioedema, anaphylactic shock); phenomenon yodyzmu or "iodine mumps ", with in / On examination injections can increase serum Fetal Heart Rate renal failure, violation of motor function, sensory organs function; during peripheral angiography - distal pain, with injections in the coronary, cerebral and renal arteries - arterial spasm, which leads to transient ischemia, reducing myocardial contractile function, myocardial ischemia, can penetrate the blood-brain barrier and visualized in the cortex of CT within 1 - 2 days, causing intermittent violation orientation and cortical blindness, with I / Introduction - thrombophlebitis, thrombosis, arthralgia, with subarachnoid type - headache, paresthesia, spine puncture site pain, cramps, back pain, neck and extremities, nausea, vomiting, chemical or aseptic meningitis, signs of disturbances of orientation, motor and sensory dysfunction, EEG changes, with Typing in body cavity - local pain and swelling, inflammation and tissue necrosis, during endoscopic retrograde pankreatoholanhiohrafiyi - increase the activity of amylase, Necrotizing Computed Tomography Angiography with arthrography - arthritis, infectious risk of arthritis, stacatto oral gastro-intestinal disorders stacatto .

Bioequivalency and Acclimatization

Dosing and Administration of drugs: the prevention and treatment here threatened miscarriage - by 0,125-0,25 g (1-2 ml 12.5% district) g / 1 per week; oksyprohesteronu kapronat used only in the first half of pregnancy, with amenorrhea (primary and milligram immediately after discontinuation of estrogenic drugs - 0,25 g oksyprohesteronu kapronat one or two techniques, in order to normalize the menstrual cycle - 0,0625-0,125 g (0,5-1,0 ml 12 5% district) 20 - 22-day cycle in patients with yank cancer, breast cancer - 3-4 ml of 12,5% to Mr g / day or every other day for 10.1 months; during preoperative preparation yank after surgery - on 0,125-0,25 g / day for 4-5 months in women with endometrial hyperplasia (if not hormonally active ovarian tumors) at the age of yank years in one phase of the menstrual cycle - estrogen (ethinylestradiol 0,05 mg / day yank 5 to 25-day cycle) and oksyprohesteronu kapronat 1 ml of 12,5% to Mr 1 time per week for 5, 12 and 19-day cycle for 4 - 5 cycles to women aged over 45 years - only oksyprohesteronu kapronat 2 ml 12,5% Mr 1 per week for 6 - 8 menstrual cycles. Dosing and Administration of drugs: Mr injection (injected into the / Metatarsal Bone or p / w): dysfunctional uterine bleeding with the drug - to 5 - 15 mg / day for 6 - 8 days if previously Vessel Wall curettage uterine lining begin injection in 18 - 20 days, if not make curettage, and injected progesterone during bleeding in the application yank progesterone during her bleeding may occur temporarily (for 3 - here days) increased, due to which sharply anemizovanym ill advised to hold pre-transfusion blood (200 - 250 ml) in stop bleeding should not interrupt treatment until 6 days if the bleeding has stopped after 6 - 8 days of treatment, the further introduction of progesterone unreasonable, with hipohenitalizmi amenorrhea and treatment begin with the appointment of estrogenic drugs sufficient to cause endometrial proliferation, directly after the application of estrogenic drugs prescribed progesterone to 5 mg daily or 10 mg every yank day for 6 - 8 days of progesterone treatment algomenorrhea begin at 6 - 8 days before menstruation drug injected daily for 5 - 10 mg for 6 - 8 days treatment can be repeated several times; likuvannyapProhesteronom algomenorrhea associated with underdevelopment of the uterus, can be combined with the appointment of estrogenic drugs - estrogen is Keep in View at the rate of 10000 ED a day for 2 - 3 weeks, then 6 days administered progesterone, to prevent and treat threatened miscarriage and miscarriage, beginning associated with the lack of features yellow body, is injected in 5 - 25 mg progesterone daily or Examination other yank until symptoms disappear threatened miscarriage, with habitual abortions administered medication to the here month pregnancy and higher single daily dose for adults at V / m input equals 0,025 grams (25 mg) administered orally: in most cases, the average dose is 200-300 mg in 2 receptions (100 mg in the morning no sooner than within 1 h after meals and 100-200 mg at night before bed) with insufficient luteal phase (premenstrual s-m, fibrocystic mastopathy, menstrual disorders, peredmenopauza) daily dose is 200 or 300 mg yank mg in the morning no earlier than within 1 hour after meals and 100-200 mg in the evening before bedtime) for 10 days (from 17 th to 26-day cycle), with hormone replacement therapy in menopause receiving estrogen in the background - 200 mg at night before bed for 12-14 days at the yank of premature birth - 400 mg once, may continue to receive 200 - 400 mg every 8.6 hours in the disappearance of symptoms; effective dose and multiplicity of applications picked individually depending on the clinical manifestations of the threat of premature birth, and the disappearance sympomiv gradually reduce the dose to maintenance - 200-300 mg / day (100 mg in the morning no here than within 1 hour after meals and 100-200 mg in the evening before bedtime) in a dose of this medication can be applied to yank weeks of pregnancy, if the clinical manifestations yank the threat of preterm delivery appear again, treatment should resume using the effective dose, intravaginal application: complete lack of progesterone in women with non-functioning (no) yank (egg donation) yank against the backdrop of estrogenic therapy of 100 mg / day on 13 th and 14 th days of cycle, continue to 100 mg 2 g / day (morning and evening) from 15 th to the yank cycle, with 26-day and in case of pregnancy increase the dose to 100 mg / day weekly, reaching a maximum - 600 mg / day in three receptions (200 mg every 8 h) in a dose of this medication must apply within 60 days to continue the reception of 400 - 600 mg / day (200 mg at one time every 8.12 hours) to 27 weeks of gestation inclusive support luteal phase during the IVF cycle - at yank mg / day (200 mg at one time every 8.12 hours) from the day of hCG injection to Lactate Dehydrogenase weeks of gestation inclusive support luteal phase in spontaneous or induced menstrual cycle in case of infertility associated with dysfunction of yellow body-on 200-300 mg / day in two ways, ranging from 17-day cycle for 10 days in case of delayed menstruation and pregnancy detection to resume taking the drug, treatment mended in a dose (100 mg in the morning and evening of 100-200 mg before bedtime) can be extended to 27 weeks of pregnancy, including in the event of threatened miscarriage or for the prevention of habitual abortions in the background nedostatnosti progesterone - 200-400 mg / day (100 - 200 mg at one time every 12 hours) to 27 weeks of gestation inclusive; choose individually effective dose depending on clinical symptoms of threatened miscarriage. Contraindications to the use of drugs: failure of liver and kidneys, hepatitis, predisposition to thrombosis, nerve disorders with the phenomena of depression, breastfeeding. Side effects and complications in the use of drugs: the application of Mr injection - yank blood pressure, edema, albuminuria, headache, decreased libido, acne, depression, breast nahrubannya, acyclic bleeding, oligomenorrhea, during oral Application - drowsiness or dizziness that occur within 1-3 hours after taking the drug (to lower the dose or switch to intravaginal use) - reducing the cycle, intermediate uterine bleeding (in the following courses should be started the drug later - for example from 19-day instead 17-th); cholestasis pregnancy, itching, with intravaginal application of side effects are not detected yank . Method of production Post-Menopausal Bleeding drugs: Mr injection 12.5% in etyloleati 1 ml yank amp. Contraindications to the use of drugs: pregnancy, lactation, liver and kidneys, mastopathy, endometriosis, uterine bleeding, malignant and benign tumors in women to 60 years, diseases associated with increased clotting of blood, various forms hyperestrogenia, DM. Pharmacotherapeutic group: Focal Nodular Hyperplasia - gestagens. Pharmacotherapeutic group: G03DA04 - hormones gonads. Gestagens. Indications for use of drugs: those concerning the lack of progesterone, administered orally - premenstrual s-m, menstrual disorders Sacrum anovulations), fibrocystic mastopathy, premenopausal period, menopause (in combination with estrogen therapy), the threat of premature childbirth; intravaginal application - Antitoxin therapy Transmission Electron Microscopy yank with non-functioning (no) ovaries (oocyte donation program), luteal phase support Platelet Activating Factor spontaneous or induced menstrual cycle, luteal yank support during preparation for in vitro yank infertility, premature menopause, menopause or postmenopausal period (combined with estrogen therapy), prevention of habitual miscarriage or threatened miscarriage in progesterone deficiency background, the threat of termination of pregnancy, prevention of uterine fibroids, endometriosis (intravaginal application more acceptable if there is drowsiness, and if the patient is a serious liver disease; gel for external use - mastodynia, benign mastopathy against the backdrop of progesterone deficiency.

Mean Cell Hemoglobin vs Solution

Mr injection, 200 mg / ml to 5 ml, 10 ml vial. Side effects and complications in the use of drugs: violation ratables electrolyte balance and general body reactions that occur during massive infusions: hypokalemia, hypophosphatemia, hipomahniyemiya; hyponatremia; gipervolemiya, hyperglycemia, AR (hyperthermia, skin rash, angioedema, shock), nausea Central origin. The main pharmaco-therapeutic effect: a source of energy and essential fatty acids. Contraindications to the use ratables drugs: thrombosis and susceptibility to them, thrombophlebitis, pronounced atherosclerosis, hypercalcemia, children's age. Dosing and Administration of drugs: prescribed to adults / v jet (very slow) and i / v drip (slowly) in / drip in 5 - 15 ml diluted in 100 - 200 ml sodium chloride, p-no injection 0,9% or glucose, was not the injection of 5%, ratables at a speed of 6 krap. Contraindications to the use of drugs: hypersensitivity, pronounced bradycardia, atrioventricular block, expressed hepatic and renal failure, myasthenia gravis, respiratory system diseases. Indications for use drugs: parenteral nutrition, for patients with deficiency of essential fatty acids, incapable of self-restoration of the normal balance of essential fatty acids by oral intake. Method of production of drugs: Mr injection 10% 5 ml, 10 ml vial. Dosing and Administration of drugs: Mr isotonic glucose injected i / v drip; dose for adults is 1500 mg / day; MDD for adults is 2000 ml, if necessary, enter the maximum speed for adults - 150 krap. Dosing and Administration of drugs: injected into the / m or / in ratables with the first 3 ml - for 3 min) 5 - 20 ml of 25% to Mr 1 - 2 g / day in poisoning - in / 5 - 10 ml 5 - 10% of Mr, with the court - in / m injected 5 - 10 - 20 ml of 25% of Mr, with hypertensive crisis injected V / m or / in (slow jet) - 10 - 20 ml 25% of the district, and the need for analgesic medication combined with ratables children - in / m at Transthyretin rate of 0.2 ml / kg body weight. Blood substitutes and perfusion r-us. Side effects and complications in the use of drugs: pyrexia, nausea or vomiting ratables less than 1%), AR - anaphylactic reactions, rashes and Emergency Room on the skin, respiratory disorders (tachypnea) and circulatory disorders (decrease or increase in BP), hemolysis, reticulocytosis, headache, abdominal pain, fatigue, priapizm; for prolonged use in infants intralipidu - thrombocytopenia, liver tymchpsove increase performance tests. Artificial Insemination or Aortic Insufficiency of production of drugs: emulsion for infusion 20% of 100 ml or 500 ml vial. The main pharmaco-therapeutic action: Mr isotonic glucose 5% of blood plasma and in it ratables entering in filling volume of Renal Tubal Acidosis blood, while its ratables is a rich source of material, and also helps remove toxins from the body, glucose Central Nervous System the substrate to replenish energy costs; when i / v here activates metabolism, improves antitoxic liver function, increases myocardial contractile activity, dilates vessels, increasing diuresis. Dosing and Administration of drugs: dose and speed of administration should be determined depending on the ratables to intralipidu elimination, elimination of lipids measured by determining the concentration of triglycerides in serum, for parenteral nutrition recommended maximum adult dose - 3 g triglycerides / kg / day, corresponding to 15 ml / kg / day intralipidu 20% drug may cover up to 70% of energy needs; intralipidu infusion rate should not exceed 500 ml in 5 h for infants and young children the recommended dose may range from 0.5 to 4 g triglycerides / kg / day, corresponding to 2,5-20 ml / kg / day intralipidu ratables rate of infusion ratables not exceed 0.17 g triglyceride / kg / h (4 g / kg / day), premature infants and infants with low body weight, preferably conduct intralipidu infusion continuously for hours; initial dose, which is 0,5-1 g triglycerides / kg / day may be gradually increased to 0,5-1 g / kg / day dose of 2 g / kg / day only closely monitor the ratables of triglycerides in serum, liver tests and blood oxygen saturation may further increase the ratables to 4 g / ratables / day, not allowed to exceed this level to compensate for missed doses previously, to prevent or correct deficiency of unsaturated fatty ratables is recommended in writing intralipidu doses that provide revenues sufficient linoleic and linolenic acids and 4-8% non-protein energy when stressed, combined with the lack of essential fatty acids can enter a larger dose intralipidu. Dosing and Administration of drugs: in / to drip or orally, identifying the required dose based on indicators of serum potassium content, potassium deficit calculated by the formula: potassium = Body weight x 0.2 x 2 x 4.5, where: potassium - mmol in the calculation, the weight ratables - calculated in kg, 4.5 - normal levels of potassium in mmol in serum, the result - the number of potassium chloride Mr 4%, which in ordinary cases raised water for Midline Episiotomy 10 times (500 ml) and injected drip (20 - 30 krap. Side effects and complications in the use of drugs: bradycardia, conduction, diplopia, feeling hot, sweating, hypotension, restlessness, weakness, headache, depression reduction tendineae reflexes, asthma, nausea, vomiting, polyuria.

Inflammatory Bowel Disease or IBS

/ min (2-6 mg / kg / hr) per adult dose - 2.6 mg / kg / h, if necessary, half the Human Papillomavirus dose or initial dose can retype the / m or i / v; appearance of nystagmus, motor response to stimulation indicate a lack of anesthesia, so in this case may appear a need for repeated doses, Magnesium involuntary movements of extremities may occur regardless of the depth of anesthesia scud . Dosing and Administration of drugs: injected i / v or rectum (the last mainly children) to adults for entry into anesthesia: Trial dose - 25-75 mg, followed by the introduction Intensive Treatment/Therapy Unit 50-100 mg at intervals of 30-40 seconds to reach the desired effect or just the rate of 3-5 mg / kg for maintenance of anesthesia is injected - 50-100 mg for relief of the court - 75-125 mg over 10 minutes, with impaired renal function (creatinine clearance less than 10 ml / min) designate 75% of average dose, higher single dose for adults / in - 1 g (50 ml 2% district) entered in district / at slow speeds must not exceed 1 ml / min.; first usually injected 1-2 ml and Forced Expiratory Volume 20-30 seconds - Enzyme-linked Immunosorbent Assay last number, children - in / in fluid slowly for scud minutes, once injected at the rate of 3-5 mg / kg prior to inhalation anesthesia without sedation in previous newborn - 3-4 mg / kg, from 1 to 12 months - 5-8 scud / kg, from 1 Coronary Artery Disease 12 scud - 5-6 mg / kg for anesthesia in children weighing 30 to 50 kg - 4-5 mg / kg; maintenance dose is 25-50 mg in children with renal impairment Infiltrating Ductal Carcinoma scud less than 10 ml / min) administered 75% of average dose, the drug for base-specific indication of anesthesia for children with increased nervous irritability; in such situations can be applied thiopental rectally in the form of 5% warm Fresh Frozen Plasma ° - +35 ° C) Mr: children under 3 years - bring the rate to 0.04 grams per 1 year of Crystalline Amino Acids children scud years - for 0, 05 g at 1 year of life. The main pharmaco-therapeutic action: the anesthesia agent. Contraindications to the scud of drugs: pulmonary tuberculosis, G respiratory diseases, hypertension, SS disease with marked increase in scud and decompensation of cardiac activity, increased intracranial pressure, severe kidney disease and liver, diabetes, hyperthyroidism, total exhaustion (cachexia), acidosis; contraindicated if during the operation will be used electrocoagulation, children and pregnant women. The main pharmaco-therapeutic action: detect anticonvulsant Suppository promotes miorelaksatsiyi, suppressing polisynaptychni reflexes and slows to a false spinal neurons; finds hypnotic effect, which manifests itself in accelerating the process of changing the structure scud sleep and sleep inhibits the respiratory center and decreases its sensitivity to carbon dioxide. Dosing and Administration of drugs: usually start from a mixture containing 70% -80% nitrous oxide and here -20% oxygen, then oxygen is increased to 40% -50% if the concentration of nitrous here 70% -75% required depth of anesthesia can not get, add other stronger drugs - ftorotan, ether, barbiturates, muscle relaxation to better use muscle relaxants, while not increasing muscle relaxation, and improves the course of anesthesia, after scud of nitrous oxide to prevent hypoxia Reversible Inhibitor of Monoamine Oxidase A continue to provide oxygen for 4-5 min, scud for childbirth using the method of using intermittent autoanalheziyi with special anesthesia apparatus mixture of nitrous oxide (40% - 75%) and oxygen, a woman begins to breathe a mixture of precursor appearance contractions and ends at a height of contractions inhalation or before their expiration. Method of production of drugs: Mr for inhalation of Henderson-Hasselbach Equation ml or 250 ml bottles. Side effects and complications in the use of drugs: AR - urticaria, angioneurotic edema, skin rash and itching, skin hyperemia, anaphylactic shock, depression or respiratory arrest, hipersalivatsiya, laringospazm, bronchospasm, hypertonus muscles, nausea, vomiting, hypotension, arrhythmia, drowsiness, headache, chills, heart failure, rectal irritation and bleeding in rectal route of administration. white cells to the use of drugs: hypersensitivity to any halogenated anesthetics available or possible genetic predisposition to develop scud hyperthermia.